Prulifloxacin

Drugbox
IUPAC_name =

---

CAS_number = 123447-62-1
ATC_prefix = J01
ATC_suffix = MA17
PubChem = 65947
DrugBank =
C=21|H=20|F=1|N=3|O=6|S=1
molecular_weight = 461.463403 g/mol
bioavailability =
protein_bound =
metabolism = By esterases, to ulifloxacin
elimination_half-life = 7.7 to 8.9 hours
excretion = Renal and fecal
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = Oral

Prulifloxacin (INN, codenamed NM441 and AF 3012; trade names Quisnon and Sword) is a broad-spectrum fluoroquinolone antibiotic. It is a prodrug, and is metabolized in the body to the active compound ulifloxacin (also known as AF 3013). Prulifloxacin has a long half-life and may therefore be taken only once a day.cite journal |author=Keam SJ, Perry CM |title=Prulifloxacin |journal=Drugs |volume=64 |issue=19 |pages=2221–34; discussion 2235–6 |year=2004 |pmid=15456336 |doi= |url=]

In clinical trials, prulifloxacin appeared as effective as ciprofloxacin, co-amoxiclav or pefloxacin in the treatment of bronchitis exacerbations or lower urinary tract infections. It was tolerated as well as ciprofloxacin.

Prulifloxacin has been approved for use in Japan. [cite journal |author=Anonymous |title=Prulifloxacin 'Quisnon'; Nippon Shinyaku has been approved in Japan |journal=Inpharma |year=2002 |volume=1 |issue=1362 |pages=22 |url=http://www.ingentaconnect.com/content/adis/inp/2002/00000001/00001362/art00025] In the United States, it is undergoing phase III clinical trials for the treatment of traveler's diarrhea. [cite press release |url=http://www.medicalnewstoday.com/articles/120214.php |title=Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase 3 Clinical Trial |date=September 3, 2008 |publisher=Medical News Today Retrieved October 11, 2008.]

References